Doctors say they’re filling a void left by CDC on vaccines. Here’s what to know about flu, Covid-19 and RSV this fall
As CDC Stays Silent on Fall Vaccines, Medical Groups Step In With Their Own Guidance
Healfromzero.com – Autumn brings a familiar public-health question every year: which shots should you get before respiratory viruses sweep through communities? For decades, the answer came from a single federal source. This year, that source has gone largely quiet, leaving physicians, parents, and patients to navigate a landscape of uncertainty while influenza, SARS-CoV-2, and respiratory syncytial virus prepare to circulate once again.
The US Centers for Disease Control and Prevention, which traditionally kicks off a coordinated fall immunization campaign each September, has not released new seasonal recommendations for RSV vaccination or updated Covid-19 boosters for the current period. Instead, on Tuesday, the agency posted a brief update to its website confirming that the influenza guidance originally published in its July 2025 immunization schedule continues to apply through the 2026–2027 flu season. Notably, that update makes no reference to the first mRNA-based flu vaccine, which received FDA clearance for older adults just last month.
A Federal Vacuum, Filled by Independent Review
With the agency's usual role effectively suspended, two organizations moved to close the gap. The American Medical Association and the Vaccine Integrity Project at the University of Minnesota conducted parallel, independent evaluations of this fall's available vaccines covering flu, SARS-CoV-2, and RSV. Their findings appeared in the peer-reviewed journal JAMA on Wednesday.
Those reviews, in turn, fed directly into a set of 2026–27 respiratory-virus immunization recommendations issued the same day by four major professional bodies: the American Academy of Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America. Together, the documents specify which vaccines are advised for which populations and identify the optimal timing for administration.
Why the Gap Matters
Dr. Bruce Gellin, board chair of the Vaccine Integrity Project and professor of medicine at Georgetown University, framed the situation at a news briefing as a departure from a long-standing institutional norm.
"For more than 60 years, the United States has benefited from an established federal process for evaluating vaccine evidence and translating that science into recommendations for the American public. At the center of that process were the Centers for Disease Control and its Advisory Committee on Immization Practices, the ACIP."
Gellin acknowledged the current reality without softening its implications.
"Unfortunately today, the federal government is not fulfilling that responsibility in the way that it historically has. But the need for that work has not disappeared. Influenza, SARS-CoV-2 and the RSV viruses will circulate again this fall and winter."
He emphasized that the practical stakes remain unchanged regardless of bureaucratic silence.
"Clinicians will still have patients to care for. Parents will still have decisions to make for their children, and older Americans, pregnant women and people with underlying health conditions will still need to know how best to protect themselves. We cannot allow the breakdown of a federal process to create a vacuum in evidence-based vaccine guidance."
What the New Recommendations Actually Say
The guidance documents break down eligibility by virus and by patient population. For RSV, the advised groups include adults aged 50 and older who carry high-risk medical conditions, all individuals over age 75, pregnant people, and infants. Dr. Sarah Nosal, president of the American Academy of Family Physicians, clarified the dosing question many patients will ask:
"People age 50 and older with high-risk conditions, and everyone over 75 years old, should get one dose. This is not an annual vaccine. If you got one before, you do not need a new one this year. Getting one should protect you throughout the entire season."
For influenza, the guidance aligns with the existing schedule: annual vaccination remains recommended for essentially everyone six months and older. The updated mRNA flu option now approved for older adults adds a choice that the CDC's brief Tuesday update conspicuously omitted. Updated formulations of the Covid-19 vaccine, recently cleared by the FDA, are rolling out and becoming accessible at pharmacies and clinics.
Coverage, Access, and the Broader Question
Practical access appears to be holding steady. Flu and RSV vaccines are already stocked at major pharmacy chains, and the newly approved Covid-19 formulations are entering distribution. Nosal added a note of reassurance regarding cost:
"And really reassuringly, insurers have indicated to the major groups that they will cover these respiratory virus immunizations."
She underscored the public-health rationale behind the recommendations in a written statement:
"Vaccines are one of medicine's greatest success stories. They prevent serious illness, reduce hospitalizations and long-term complications and save lives. As federal guidance evolves, the science behind vaccines remains strong. These recommendations are grounded in the latest evidence, informed by public health experts and shaped by what family physicians are seeing every day in their patients."
The US Department of Health and Human Services did not respond to requests for comment on the groups' recommendations. Meanwhile, physicians have expressed concern that an executive order issued under the current administration could further erode public confidence in vaccination, steering families away from preventive care at precisely the moment respiratory viruses peak. The independent medical guidance released this week is, in effect, an attempt to ensure that clinical decision-making does not stall while the question of federal authority remains unresolved.
For patients and caregivers, the practical takeaway is straightforward: the vaccines exist, they are available at pharmacies and clinics, insurers have signaled coverage, and four major specialty societies have published clear, evidence-based eligibility criteria. The absence of a single federal banner campaign does not change the biology of the viruses arriving with the season, nor does it alter the clinical consensus on who benefits from protection.
Related Reading
Frequently Asked Questions
What is Doctors say they re filling a void?Doctors say they re filling a void is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.
Why does Doctors say they re filling a void matter?Doctors say they re filling a void matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.